MgCaCo3 versus CaCo3 in peritoneal dialysis patients – A cross-over pilot trial

Peritoneal Dialysis International

Volumn 35, Issue 1, 2015, Pages 31-34

  Evsanaa, Baigalmaa ^a   Liu, Irene ^b   Aliazardeh, Babak ^b   Mahdavi, Sara ^b   Bajwa, Gursarn ^b   Gula, Jerry ^b   Tam, Michelle ^b   Sze, Elena ^b   Roscoe, Janet M ^b   Tam, Paul Y ^b   Sikaneta, Tabo ^b  

^a MONGOLIAN NATIONAL UNIVERSITY OF MEDICAL SCIENCES   (Mongolia)

^b SCARBOROUGH HOSPITAL   (Canada)

Author keywords

Adverse effects; Compliance rates; Magnesium calcium carbonate; Phosphate binders

Indexed keywords

CALCIUM CARBONATE; MAGNESIUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D; MAGNESIUM;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; HUMAN; HYPERPHOSPHATEMIA; KIDNEY GRAFT; MAGNESIUM BLOOD LEVEL; MALE; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PERITONITIS; PHOSPHATE BLOOD LEVEL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ADVERSE EFFECTS; AGED; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PROCEDURES; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; CALCIUM CARBONATE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPHOSPHATEMIA; MAGNESIUM; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PILOT PROJECTS; RISK ASSESSMENT; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84930921152     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2013.00129     Document Type: Article

References (7)

1. Emmett M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int 2004; 66:S25–32.
2. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009; 4(6):1089–96.
3. de Francisco ALM, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010; 25(11):3707–17.
4. Tzanakis IP, Papadaki AN, Wei M, Kagia S, Spadidakis VV, Kallivretakis NE. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial. Int Urol Nephrol 2008; 40(1):193–201.
5. Parsons V, Baldwin D, Moniz C, Marsden J, Ball E, Rifkin I. Successful control of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis using magnesium carbonate and calcium carbonate as phosphate binders. Nephron 1993; 63(4):379–83.
6. Yasuda G, Shibata K, Takizawa T, Ikeda Y, Tokita Y, Umemura S, et al. Prevalence of constipation in continuous ambulatory peritoneal dialysis patients and comparison with hemodialysis patients. Am J Kidney Dis 2002 Jun; 39(6):1292–9.
7. Jung GJ, Gil HW, Yang JO, Lee EY, Hong SY. Severe hypermagnesemia causing quadriparesis in a CAPD patient. Perit Dial Int 2008 Mar–Apr; 28(2):206.